SBIR/STTR federal seed-funding programs need reauthorization

18 August 2022
congress_washington_politics_big

Two federal programs that have been driving innovation for 40 years by providing seed funding to entrepreneurs are in danger of running out of money - unless Congress acts by September 30, according to the USA’s Biotechnology Innovation Organization (BIO).

The  Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) programs typically give up to $250,000 for the first year of development of an idea and up to $750,000 more if the idea proves feasible.

The grants provide good value - generating “a 22:1 return for every federal dollar spent,” with “a commercialization rate of between 50-60% for SBIR/STTR investments,” according to the Arizona Bioindustry Association (AZ BIO). Many BIO members have used the grants to commercialize innovations.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology